AstraZeneca

H1 2022 Results

Conference call and webcast
for investors and analysts

29 July 2022



Forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group’s control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective IP protection and IP challenges by third parties; the impact of competitive pressures including expiry or loss of IP rights, and generic competition; the impact of price controls and reductions; the impact of economic, regulatory and political pressures; the impact of uncertainty and volatility in relation to the UK’s exit from the EU; the risk of failures or delays in the quality or execution of the Group’s commercial strategies; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group’s medicines; the impact of reliance on third-party goods and services; the risk of failure in information technology, data protection or cybercrime; the risk of failure of critical processes; any expected gains from productivity initiatives are uncertain; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to adhere to applicable laws, rules and regulations; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; the risk of failure to adhere to increasingly stringent anti-bribery and anti-corruption legislation; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group’s financial position; and the impact that global and/or geopolitical events such as the COVID-19 pandemic and the Russia-Ukraine war, may have or continue to have on these risks, on the Group’s ability to continue to mitigate these risks, and on the Group’s operations, financial results or financial condition. Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast.

H1 2022 Results: conference call agenda



CEO Opening Remarks	Pascal Soriot	*Chief Executive Officer*
Financial Results	Aradhana Sarin	*Chief Financial Officer*
Oncology	Dave Fredrickson Susan Galbraith	*EVP Oncology Business* *EVP Oncology R&D*
BioPharmaceuticals, Emerging Markets	Ruud Dobber Mene Pangalos	*EVP BioPharmaceuticals Business* *EVP BioPharmaceuticals R&D*
Rare Disease	Marc Dunoyer	*Chief Executive Officer Alexion*
CEO Closing Remarks, Q&A	Pascal Soriot	*Chief Executive Officer*

AstraZeneca

CEO Opening Remarks

Pascal Soriot

Chief Executive Officer



H1 2022: key updates

Progress against our strategic objectives

Robust growth

Supported by diverse portfolio

- Total Revenue $22.2bn (+48%)
- Core EPS $3.61 (+44%)
- Increasing 2022 Total Revenue guidance at CER
- Increased interim dividend to $0.93

Broad-based performance

Delivering value to patients

- **Oncology** $7.5bn (+22%)
- **BioPharmaceuticals**[1] $10.4bn (+31%)
  - **CVRM**[1] $4.6bn (+19%)
  - **R&I** $3.0bn (+3%)
  - **V&I** $2.8bn (>2x)
    - *Vaxzevria*[2] $1.6bn (+42%)
    - *Evusheld* $914m (n/m)
- **Rare Disease**[1] $3.5bn (+10%)

Science-led innovation

Key developments

- *Farxiga* DELIVER Phase III data readout
  - HFpEF
- *Ultomiris* CHAMPION-NMOSD Phase III data readout
  - NMOSD
- *Imfinzi* AEGEAN Phase III pCR data readout
  - NSCLC
- *Enhertu* DESTINY-Breast04 ASCO presentation
  - HER2-low breast cancer
- *Enhertu* approval (US, EU)
  - HER2-positive breast cancer (DESTINY-Breast03)
- *Tezspire* positive CHMP opinion (EU)
  - Severe asthma (NAVIGATOR)
- *Ultomiris* positive CHMP opinion (EU)
  - gMG (CHAMPION-MG)
- *Lynparza* positive CHMP opinion (EU)
  - Early breast cancer (OlympiA)

2022 guidance: low twenties % Total Revenue growth (CER) (updated)| mid-to-high twenties % Core EPS growth (CER)

Absolute values at actual exchange rates; changes at constant exchange rates (CER) and for year-to-date (YTD) June 2022, unless stated otherwise. 1. Pro forma growth rates reported for Alexion Rare Disease based on prior year historical Alexion reporting and with inclusion of *Koselugo* and CVRM following *Andexxa* inclusion; all rates mentioned are pro forma growth rates at CER. 2. *Vaxzevria* Total Revenue' also includes Collaboration Revenue from sub-licensees that produce and supply AstraZeneca COVID-19 Vaccine under their own trademarks; EPS = earnings per share; n/m = not meaningful; CVRM = Cardiovascular, Renal and Metabolism; R&I = Respiratory and Immunology; V&I = Vaccines and Immune Therapies; HFpEF = heart failure with preserved ejection fraction; NSCLC = non-small cell lung cancer; HER2 = human epidermal growth factor receptor 2; NMOSD = neuromyelitis optica spectrum disorder; pCR = pathologic complete response; CHMP = Committee for Medicinal Products for Human Use; gMG = generalised myasthenia gravis.

AstraZeneca

Investing efficiently to deliver long-term sustainable growth

Unprecedented pipeline delivery

In the year to date:

- *13 Phase III starts*
- *5 positive pivotal trial read outs*
- *20 submission acceptances*
- *>120 projects in Phase II/III*

Data-driven expansion for high value opportunities

- *Dato-DXd*
- *Enhertu*
- *AZD5305 (PARP-1 sel)*
- *IO bispecifics*
- *tozorakimab*
- *eplontersen*

Investment in discovery and new technology

- *ADCs*
- *Cell therapy*
- *PROTACs*
- *T-Cell engagers*
- *Oligo/mRNA-based therapies*
- *Computational pathology*
- *AI & machine learning*

Driving continuous productivity improvements

- *Remote clinical trial capabilities*
- *Process improvements: data flow, next gen regulatory, protocol optimisation*
- *Internalisation of clinical operations*
- *Rigorous portfolio prioritisation e.g., adavosertib, AZD8601 (VEGF), AZD7648 (DNAPK)*

Dato-DXd = datopotamab deruxtecan; PARP-1 sel = Poly [ADP-ribose] polymerase 1 selective; ADC = antibody drug conjugates; IO = immuno-oncology; PROTACs = PROteolysis TArgeting Chimeras; Oligo = oligonucleotides; AI = artificial intelligence; VEGF = vascular endothelial growth factor; DNAPK = DNA-dependent protein kinase.

AstraZeneca

Strong 2022 outlook, well positioned to deliver industry-leading growth 2025+

Pipeline momentum

Key upcoming Phase III readouts

H2 2022

- *Imfinzi* – **EMERALD-1** – locoregional HCC
- capivasertib – **CAPItello291** – HR+/HER2-neg BC
- *Fasenra* – **MESSINA** – eosinophilic oesophagitis

2023

- camizestrant – **SERENA-6** – HR+/HER2-neg BC
- Dato-DXd – **TROPION-Lung01** – 3L NSCLC
- *Enhertu* – **DESTINY-Breast06** – HER2-low BC
- danicopan – PNH with EVH

Well positioned to deliver growth 2025+

Industry-leading portfolio and pipeline

- **Robust lifecycle management**
- **Innovative late-stage pipeline**
- **Strategic business development**
- **Attractive loss of exclusivity profile**

Multiple opportunities to unlock pipeline value

Selected next-wave NMEs with significant potential 2025+

BioPharmaceuticals	Oncology	Rare Disease
eplontersen (LICA)	Dato-DXd (TROP2 ADC)	ALXN2050 (oral Factor D)
AZD4831 (MPO)	MEDI5752 (PD1-CTLA4)	ALXN1720 (C5 mini-body)
cotadutide (GLP-1/Glucagon)	AZD2936 (PD1-TIGIT)	ALXN1850 (ngHPP)
tozorakimab (IL-33)	camizestrant (ngSERD)	
AZD8233 (PCSK9 ASO)	capivasertib (AKT)	
ngCOVID-19 LAAB	AZD5305 (PARP-1sel)	

HCC = hepatocellular carcinoma; HR+ = hormone receptor positive; HER2- = human epidermal growth factor receptor 2 negative; BC = breast cancer; Dato-DXd = datopotamab deruxtecan; 3L = 3rd line; NSCLC = non small cell lung cancer; HER2-low = HER2 IHC score 1+ or 2+ with ISH test negative; PNH = paroxysmal nocturnal haemoglobinuria; EVH = extravascular hemolysis; NME = new molecular entity; LICA = ligand-conjugated antisense; MPO = myeloperoxidase; GLP-1 = glucagon-like peptide-1; IL-33 = Interleukin 33; PCSK9 ASO = proprotein convertase subtilisin/kexin type 9 antisense oligonucleotide; ng = next generation; LAAB = long –acting antibody; TROP2 ADC = trophoblast cell surface antigen 2-directed antibody-drug conjugate; PD-1 = programmed cell death protein 1; CTLA-4 = cytotoxic T-lymphocyte-associated antigen 4; TIGIT = T-cell immunoreceptor with Ig and ITIM domains; ngSERD = next generation selective estrogen receptor degrader; AKT = serine/threonine protein kinase; PARP-1sel = polymerase (ADP-ribose)-1 selective; ngHPP = next generation hypophosphatasia.

AstraZeneca

Financial Results

Aradhana Sarin
Chief Financial Officer



Reported Profit and Loss

Continued strong top-line growth

	H1 2022 $m	CER change %	% total revenue	Q2 2022 $m	CER change %	% total revenue
Total Revenue	**22,161**	**48**	**100**	**10,771**	**37**	**100**
- Product Sales	*21,610*	*47*	*98*	*10,630*	*38*	*99*
- Collaboration Revenue	*551*	*130*	*2*	*141*	*(20)*	*1*
Gross margin	69.9%	-4 pp		71.8%	-2 pp	
Operating expenses[1]	14,454	52	65	7,356	51	68
- R&D expenses	4,679	35	21	2,546	44	24
- SG&A expenses	9,521	62	43	4,681	56	43
Other operating income	219	(83)	1	122	(5)	1
Operating profit	1,417	(49)	6	539	(53)	5
Tax rate	6.5%			-45.7%		
EPS	**$0.48**	**(66)**		**$0.23**	**(46)**	

Absolute values at actual exchange rates; changes at CER. Gross margin excludes the impact of collaboration revenue and any associated costs, thereby reflecting the underlying performance of Product Sales.

1 . Total operating expenses include distribution, R&D and SG&A expenses. R&D = research and development; SG&A = sales, general and administration; pp = percentage points; n/m = growth rate not meaningful; CER = constant exchange rates.

Core Profit and Loss

Continued operating leverage

	H1 2022 $m	CER change %	% total revenue	Q2 2022 $m	CER change %	% total revenue
Total Revenue	**22,161**	**48**	**100**	**10,771**	**37**	**100**
- Product Sales	*21,610*	*47*	*98*	*10,630*	*38*	*99*
- Collaboration Revenue	*551*	*n/m*	*2*	*141*	*(20)*	*1*
Gross margin	81.1%	+6 pp		82.9%	+8 pp	
Operating expenses[1]	10,953	33	49	5,697	36	53
- R&D expenses	4,617	38	21	2,431	40	23
- SG&A expenses	6,083	29	27	3,137	33	29
Other operating income	210	(84)	1	112	(13)	1
Operating profit	7,326	71	33	3,365	87	31
Tax rate	18.3%			15.3%		
EPS	**$3.61**	**44**		**$1.72**	**89**	

Absolute values at actual exchange rates; changes at CER. Gross margin excludes the impact of collaboration revenue and any associated costs, thereby reflecting the underlying performance of Product Sales.
1 . Total operating expenses include distribution, R&D and SG&A expenses. R&D = research and development; SG&A = sales, general and administration; pp = percentage points; n/m = growth rate not meaningful; CER = constant exchange rates.

2022 guidance (CER)

Overall business strength, improved COVID-19 medicines outlook

Total Revenue

February 2022	July 2022
"a high teens" % increase	→ "low twenties" % increase

Core EPS

February 2022	July 2022
"mid-to-high twenties" % increase	= "mid-to-high twenties" % increase

- Total Revenue from COVID-19 medicines anticipated to be broadly flat vs. 2021
- Core Operating Expense expected to increase by a mid-to-high teens percentage
- Other Operating Income in H2 2022 expected to be broadly in line with H1 2022
- Emerging Markets Total Revenue expected to grow by mid-single digits; China Total Revenue expected to decline by a mid-single digit percentage
- Core Tax Rate still expected to be between 18-22%

Growth supported by a diversified business model across key disease areas and geographies

CER = constant exchange rates.

Net debt and capital allocation priorities

Continued improvement in cash flow from operations

Net debt



Net Debt/EBITDA: 3.5x
Net Debt/EBITDA adjusted for Alexion inventory fair value uplift[2]: 2.1x

Capital allocation priorities

- Strong investment grade credit rating
- Reinvestment in the business
- Value-enhancing business development
- Progressive dividend policy[3]

EBITDA = earnings before interest, tax, depreciation and amortisation; CFO = net cash inflow from operating activities. 1. Comprises purchases and disposal of intangible assets, payment of contingent consideration from business combinations, purchase and disposal of non-current asset investments, movement in profit participation liability and disposal of investments in associates and joint ventures and payment of Acerta Pharma share purchase liability 2. EBITDA adding back the impact of $4,516m 12-month rolling period (H1 2022: $2,318m) unwind of inventory fair value uplift recognised on acquisition of Alexion AstraZeneca credit ratings: Moody's: short-term rating P-2, long-term rating A3, outlook negative. S&P Global Ratings: short-term rating A-2, long-term rating A-, outlook stable. Progressive dividend policy defined as either stable or increasing dividend per share in US dollar terms.

AstraZeneca

Oncology

Dave Fredrickson
Oncology Business

Susan Galbraith
Oncology R&D



Oncology: H1 2022

Total Revenue $7.5bn, +22%, increasing product sales and collaboration revenue



Balanced global growth across five key medicines

H1 2022: key dynamics

- *Tagrisso*, *Imfinzi* and *Lynparza* double-digit Product Sales growth; *Calquence* 87% growth; *Enhertu* revenues >2x H1 2021
- Double-digit Product Sales growth across US, Europe, Established RoW and Emerging Markets, despite a headwind in Q2 from China lockdowns
- Strong global launch momentum: *Enhertu* DESTINY-Breast03, *Lynparza* OlympiA, *Calquence* ELEVATE-TN/ASCEND in EU
- COVID-19: improving rates of diagnosis and treatment globally

Key upcoming news flow

H2 2022

- ***Lynparza*** | mCRPC reg. submission (PROpel)
- ***Imfinzi*** | HCC reg. decision (HIMALAYA)
- ***Imfinzi*** | BTC reg. decision (TOPAZ-1)
- ***Enhertu*** | mBC reg. decision (DB04)
- ***Imfinzi*** | locoregional HCC (EMERALD-1)
- **capivasertib** | HR+/HER2-neg BC (CAPItello-291)

PS = product sales; reg. decision = regulatory decision; HCC = hepatocellular carcinoma; BTC = biliary tract cancer; mCRPC = metastatic castration resistant prostate cancer; mBC = metastatic breast cancer; BC = breast cancer; DB04 = DESTINY-Breast04; HR+/HER2-neg = hormone receptor positive human epidermal growth factor receptor 2 negative.

Oncology: Q2 2022 R&D highlights

Exceptional data at ASCO, new T-cell engager for haematology

Enhertu

Phase III DESTINY-Breast04



- Establishes *Enhertu* as the **new standard of care** for HER2-low metastatic breast cancer
- Similar magnitude of **benefit across all subgroups**, including HER2 IHC status and prior CDK4/6i use

capivasertib

Phase II FAKTION



- In HR+/HER2- advanced breast cancer after relapse or progression
- **55%** of advanced HR+ tumours have an **activated PI3K/AKT/PTEN pathway**
- Phase III CAPItello-291 trial due H2 2022

Pathway-altered subgroup median OS 39.8 vs. 20 months

TNB-486

CD19xCD3 T-cell engager



- Acquisition of TeneoTwo, including TNB-486
- TNB-486 **activates and recruits T-cells** to CD19-expressing tumours where they can elicit an immune response
- In Phase I trials for **B-cell non-Hodgkin lymphoma**

ASCO = American Society of Clinical Oncology; HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry; CDK4/6i = cyclin-dependent kinases 4 and 6 inhibitors; HR+/HER2- = hormone receptor positive; human epidermal growth factor receptor 2 negative; PI3K = phosphatidylinositol-3 kinase; AKT = protein kinase B; PTEN = phosphatase and TENsin homolog; OS = overall survival; CD19 = cluster of differentiation 19; CD3 = cluster of differentiation 3. *Enhertu* developed in collaboration with Daiichi Sankyo.

Oncology: Q2 2022 R&D highlights

Showcasing the next advancement in lung cancer treatment at WCLC 2022

Tagrisso and *Orpathys*

Phase II SAVANNAH



- Overall population
  ORR 32%, mDoR 8.3m, mPFS 5.3m
- Subgroup *IHC90+ and/or FISH10+*
  ORR 49%, mDoR 9.3m, mPFS 7.1m

SAFFRON, FLAURA2 support *Tagrisso* expanded use

Dato-DXd

Phase Ib TROPION-Lung02



All cohorts (n=46)	1st-line (n=16)
ORR 39%, DCR 82.6%	**ORR 69%, DCR 100%**

- Tolerable safety profile
- NSCLC – Phase II ORCHARD trial new cohort: Dato-DXd + *Tagrisso*

Key upcoming news flow

2023

- ***Tagrisso*** | EGFRm NSCLC 1L (FLAURA2)
- ***Tagrisso*** | NSCLC unresectable Stg. III (LAURA)
- **Dato-DXd** | NSCLC 2L/3L (TROPION-Lung01)
- ***Imfinzi*** | MI bladder cancer (NIAGARA)
- ***Imfinzi*** | bladder cancer 1L (NILE)
- ***Imfinzi*** | NSCLC, neoadjuvant (AEGEAN)
- ***Imfinzi*** | liver cancer, adjuvant (EMERALD-2)
- **camizestrant** | HR+/HER2-neg BC (SERENA-6)
- **capivasertib** | TNBC, advanced (CAPItello-290)

WCLC = World Conference on Lung Cancer; ORR = overall response rate; mDOR = median duration of response; mPFS = median progression free survival; Dato-DXd = datopotamab deruxtecan; DCR = disease control rate; NSCLC = non-small cell lung cancer; EGFRm = epidermal growth factor receptor mutation; Stg. = stage; MI = muscle invasive; HR+/HER2-neg = hormone receptor positive human epidermal growth factor receptor 2 negative; BC = breast cancer; TNBC = triple negative breast cancer. *Orpathys* developed in collaboration with HUTCHMED. Dato-DXd developed in collaboration with Daiichi Sankyo.

AstraZeneca

BioPharmaceuticals

Ruud Dobber
BioPharmaceuticals Business

Mene Pangalos
BioPharmaceuticals R&D



BioPharmaceuticals: H1 2022

Farxiga's second blockbuster quarter with $1.1bn revenues

CVRM

$4.6bn, +19%



Farxiga ***Brilinta*** ***Lokelma*** Other

- *Farxiga* +62%, HFrEF and CKD launches continue
  - Fastest growing SGLT2i globally[1]

R&I

$3.0bn, +3%



Symbicort ***Fasenra*** ***Pulmicort*** ***Breztri.*** Other

- *Fasenra* +18%, leading IL-5 biologic
- *Tezspire* achieved 13% NBRx share in US[2]
- *Saphnelo* achieved 24% NBRx share in US[3]

V&I

$2.8bn, >2x



Vaxzevria ***Evusheld*** ***Synagis*** ***FluMist***

- *Evusheld* $914m
- *Vaxzevria* $1.6bn, vast majority of initial contracts fulfilled in H1

1. IQVIA Mar – May R3M Volume Growth (DOT v. PY) 2. IQVIA Monthly SOB SUA Retail for M.E. May-2022 3. IQVIA ELAAD data 24 June 2022. Reporting changes: *Andexxa* is included in Biopharmaceuticals: CVRM (FY 2021: Rare Disease). Growth rates for CVRM are pro forma as they include pre-acquisition H1 *Andexxa* performance in comparative H1 2021 revenues. HFrEF = heart failure reduced ejection fraction; CKD = chronic kidney disease; SGLT2i = sodium glucose co-transporter-2 inhibitors; IL-5 = interleukin-5; CVRM = Cardiovascular, Renal and Metabolism; R&I = Respiratory & Immunology; V&I = Vaccine & Immune Therapies; NBRx = new-to-brand prescriptions. *Tezspire* developed in collaboration with Amgen.

Emerging Markets: H1 2022

Total Revenue $6.2bn, +16% including *Vaxzevria*[1]

Emerging Markets, +16%[2]

China, -5%; ex-China EM, +46%



- **Oncology** $1.8bn, +12%: *Tagrisso* +17%, *Lynparza* +32%
- **CVRM** $2.1bn, +12% pro forma: *Farxiga* +50%
- **R&I** $731m, -16%: *Pulmicort* -41%
- **V&I** $921m, *Vaxzevria* $720m, *Evusheld* $93m
- **Rare Disease** $206m, -8% pro forma

Ex-China, ex-*Vaxzevria* Emerging Markets +48%

1. *Vaxzevria* 'Total Revenue' also includes Collaboration Revenue from sub-licensees that produce and supply the AstraZeneca COVID-19 Vaccine under their own trademarks. 2. Growth number calculated includes revenue of *Vaxzevria*. Growth excluding *Vaxzevria* is as follows: EM total revenue growth +13%, China -7%; Ex-China EM +48%. Growth rates for CVRM are pro-forma as they include pre-acquisition H1 *Andexxa* performance in comparative H1 2021 revenues. Pro forma growth rates on medicines acquired with Alexion have been calculated by comparing H1 revenues with the corresponding prior year pre-acquisition revenues previously published by Alexion; all rates mentioned are pro forma growth rates at CER. CVRM = Cardiovascular, Renal & Metabolism; R&I = Respiratory & Immunology; V&I = Vaccines & Immune Therapies.

BioPharmaceuticals: Q2 2022 R&D

Positive Phase III trial results for *Farxiga*, eplontersen

Farxiga: HFpEF (DELIVER)

- **Statistically significant** and **clinically meaningful** reduction in CV mortality, worsening HF
- Efficacy in patients with HF with mildly reduced or preserved ejection fraction[1]
- Ongoing Phase IIb combination trials: with zibotentan in CKD (ZENITH-CKD) and with AZD9977 in HF with CKD (MIRACLE)

eplontersen: ATTRv-PN (NEURO-TTRansform)

- Co-primary endpoints met in a planned interim analysis at 35 weeks
- **Statistically significant** and **clinically meaningful** change on modified NIS+7, serum TTR concentration
- Ongoing Phase III trial in ATTR-CM (CARDIO-TTRansform)

Key upcoming news flow

H2 2022

- ***Tezspire*** | severe asthma reg. decision (EU, JP)
- **nirsevimab** | RSV reg. decision (EU)
- ***Fasenra*** | EOE (MESSINA)
- **AZD8233** | dyslipidemia (SOLANO*)

2023

- ***Farxiga*** | HFpEF reg. decision (US)
- **eplontersen** | ATTRv-PN reg. decision (US)
- ***Fasenra*** | EGPA (MANDARA), HES (NATRON)
- ***Farxiga*** | MI (DAPA-MI)

ntricular ejection fraction [LVEF] greater than 40%. HF = heart failure; CKD = chronic kidney disease 2. Simões, E, et al. Pooled efficacy of nirsevimab against RSV lower respiratory term and term infants. ESPID 2022 Congress; 2022 May 9-13; ATTRv-PN = hereditary transthyretin-mediated amyloid polyneuropathy; TTR = transthyretin; NIS+7 = Neuropathy ATTR-CM = transthyretin-mediated cardio myopathy; RSV = respiratory syncytial virus; HFpEF = heart failure with preserved ejection fraction; EPGA = eosinophilic lyangiitis; HES = hypereosinophilic syndrome; MI = myocardial infarction; EOE = eosinophilic oesophagitis; reg. = regulatory, LRTI = lower respiratory tract infections, RSV = *Phase II trial. Eplontersen developed in collaboration with Ionis Pharmaceuticals, nirsevimab commercialised in collaboration with Sanofi.

BioPharmaceuticals: Q2 2022 R&D

Nirsevimab shown to be 77.3% effective against hospitalisations[1]



The NEW ENGLAND JOURNAL of MEDICINE

RESEARCH SUMMARY

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

Hammitt LL et al. DOI: 10.1056/NEJMoa2110275

CLINICAL PROBLEM

Nirsevimab — a monoclonal antibody against the respiratory syncytial virus (RSV) fusion protein that has an extended half-life — has been shown to protect healthy preterm infants from RSV-associated lower respiratory tract infection, but its efficacy and safety in late-preterm and term infants are unknown.

CLINICAL TRIAL

Design: A multinational, phase 3, randomized, placebo-controlled trial assessed the efficacy and safety of nirsevimab for preventing RSV-associated lower respiratory tract infection in healthy infants born at a gestational age of at least 35 weeks.

Intervention: 1490 infants were randomly assigned, in a 2:1 ratio, to receive a single intramuscular injection of nirsevimab or placebo before entering their first RSV season. The primary efficacy end point was medically attended RSV-associated lower respiratory tract infection through day 150 after the injection.

RESULTS

Efficacy: The incidence of medically attended RSV-associated lower respiratory tract infection was significantly lower in the nirsevimab group than in the placebo group.

Safety: Similar types of adverse events occurred in the two groups, at similar frequencies. Most adverse events were grade 1 or 2 in severity.

LIMITATIONS AND REMAINING QUESTIONS

- The efficacy of nirsevimab was relatively lower among younger infants (≤3 months vs. >3 months of age) and among those who weighed less (<5 kg vs. ≥5 kg), although small numbers preclude firm conclusions.
- The trial enrolled infants in the northern hemisphere and in South Africa (southern hemisphere). Although the overall incidence of RSV during the trial was as expected in the northern hemisphere, measures to control the Covid-19 pandemic in South Africa limited RSV circulation, resulting in low enrollment there.

Links: Full Article | NEJM Quick Take

Medically Attended Lower Respiratory Tract Infection through Day 150

Efficacy, 74.5%; 95% CI, 49.6 to 87.1; P<0.001

Hospitalization for Lower Respiratory Tract Infection through Day 150

Efficacy, 62.1%; 95% CI, −8.6 to 86.8; P=0.07

Serious Adverse Events through Day 361

CONCLUSIONS

A single dose of nirsevimab given before the RSV season lowered the risk of medically attended RSV-associated lower respiratory tract infection in healthy late-preterm and term infants, with no safety concerns.

Laura L. Hammitt, M.D., Ron Dagan, M.D., Yuan Yuan, Ph.D., Manuel Baca Cots, M.D., Miroslava Bosheva, M.D., Shabir A. Madhi, Ph.D., William J. Muller, Ph.D., Heather J. Zar, Ph.D., Dennis Brooks, M.D., Amy Grenham, M.Sc., Ulrika Wählby Hamrén, Ph.D., Vaishali S. Mankad, M.D., Pin Ren, Ph.D., Therese Takas, B.Sc., Michael E. Abram, Ph.D., Amanda Leach, M.R.C.P.C.H., M. Pamela Griffin, M.D., and Tonya Villafana, Ph.D., for the MELODY Study Group*

- Designed and developed to protect **all infants** through their first RSV season with **a single dose**
- 79.5% effective against medically attended LRTI, including hospitalisations, caused by RSV[1]
- 77.3% effective against RSV LRTI hospitalisations
- EMA regulatory submission accepted in February under **accelerated assessment** (decision expected in H2 2022)
- US FDA **Breakthrough Therapy Designation** granted (submission expected in H2 2022)

Partnered with sanofi

1. Simões, E, et al. *ESPID.* May 2022; 2. Hammitt LL, MD et al. *NEJM.* 2022;386(9):837-846; LRTI = lower respiratory tract infections; RSV = respiratory syncytial virus. EMA = European Medical Authority; US FDA = United States Food and Drug Administration.

AstraZeneca

Rare Disease

Marc Dunoyer
Chief Executive Officer Alexion



Rare Disease: H1 2022

Strong initial demand for *Ultomiris* in gMG from both switch and naïve patients

Rare Disease

Total Revenue $3.5bn, +10% pro forma[1] H1 2022



Q2 2022: key dynamics

- **Durable growth C5 franchise (*Soliris* + *Ultomiris*), +9%**[1]
  - ***Soliris*, 2%**[1] slowing growth reflecting successful conversion to *Ultomiris,* benefit from one-off adjustment
  - ***Ultomiris*, +31%**[1] continued conversion in legacy indications (PNH and aHUS), initial uptake in gMG in US and expansion into new markets
- ***Strensiq*, +18%**[1] strong US demand and initiation trends
- ***Koselugo*, >2x** performance driven by expansion in new markets, one-time benefit from timing of certain tender market orders

1. Pro forma growth rates on medicines acquired with Alexion have been calculated by comparing H1 revenues with the corresponding prior year pre-acquisition revenues previously published by Alexion; all rates mentioned are pro forma growth rates at CER 2. Includes *Kanuma* and *Koselugo*. 3. Q3 2021 Total Revenues reported only comprise of those booked by AstraZeneca following completion of the acquisition of Alexion on 21 July 2021. In previous results announcements, *Koselugo* was included in the Oncology disease area. gMG = generalised myasthenia gravis, PNH = paroxysmal nocturnal haemoglobinuria, aHUS = atypical haemolytic uraemic syndrome.

Rare Disease: R&D highlights

Remarkable results from CHAMPION-NMO Phase III for *Ultomiris* in NMOSD



***Ultomiris*, zero adjudicated relapses** out to **73.5 weeks**[1]

Key upcoming news flow

2022

- ***Koselugo*** | NF1-PN reg. decision (JP)
- ***Ultomiris*** | gMG reg. decision (EU, JP)
- ***Ultomiris*** | NMOSD reg. submission (US, EU, JP)
- ***Soliris*** | GBS (JP)

2023

- ***Soliris*** | gMG reg. decision (CN)
- ***Koselugo*** | NF1-PN reg. decision (CN)
- **ALXN1840** | Wilson disease reg. submission (US)
- **danicopan** | PNH with EVH

1. Median (range) follow-up was 73.5 (11.0–117.7) weeks (ravulizumab) and 36.0 (1.9–117.7) weeks (placebo) NMOSD = neuromyelitis optica spectrum disorder; CI = confidence interval; reg. = regulatory; NF1-PN = neurofibromatosis type 1; PN = plexiform neurofibromas; gMG = generalised myasthenia gravis; s.c. = subcutaneous; PNH = paroxysmal nocturnal haemoglobinuria; aHUS = atypical haemolytic uraemic syndrome; GBS = Guillain-Barré syndrome; EVH = extravascular haemolysis.

AstraZeneca

CEO Closing Remarks

Pascal Soriot

Chief Executive Officer

AstraZeneca Chair Appointment

Michel Demaré to succeed Leif Johansson as AstraZeneca Chair effective April 2023

AstraZeneca Non-Executive Board Member since 2019

- Audit Committee Member since 2019
- Renumeration Committee Chair since August 2020
- Chair ad hoc Advisory Committee on *Vaxzevria*

Previously served as:

- Vice Chairman UBS Group AG (2010-2019)
- Chairman of Syngenta & Syngenta Foundation for Sustainable Agriculture (2013-2017)
- Chairman of Swiss Holdings (2013-2015)
- CFO ABB Ltd (2005-2013) Interim CEO (2008)
- CFO Europe Baxter International Inc. (2002-2004)

AstraZeneca: 2025+

Delivering growth through innovation

Robust life-cycle management

Supports durable, growing revenue base

farxiga (dapagliflozin)
IMFINZI durvalumab
CALQUENCE (acalabrutinib) 100 mg capsules
ENHERTU fam-trastuzumab deruxtecan-nxki
TAGRISSO osimertinib
Lynparza olaparib
ULTOMIRIS (ravulizumab-cwvz)
Fasenra (benralizumab)

Innovative late-stage pipeline

Continued investment in clinical stage pipeline

16 NMEs
in Phase III

>120 NME or major LCM
projects in Phase II and III

Across a number of areas of high unmet need, with first or best-in-class potential

Strategic business development

Recent clinical stage business development

- Rare Disease (Alexion)
- Dato-DXd (Daiichi Sankyo)
- Eplontersen (Ionis)
- CAEL-101 (Caelum Bio)
- NI006 (Neurimmune)

Attractive LoE profile

US LoE for selected medicines



LCM = life-cycle management; NME = new molecular entity; Dato-DXd = datopotamab deruxtecan; LoE = loss of exclusivity. *IPR settled to grant Amgen a non-exclusive, royalty-free license to launch an eculizumab biosimilar product in the US from March 2025

H1 2022 Question & Answer Session

Pascal Soriot

Executive Director and Chief Executive Officer

Dave Fredrickson

Executive Vice President, Oncology Business

Ruud Dobber

Executive Vice President, BioPharmaceuticals Business

Marc Dunoyer

Chief Executive Officer, Alexion

Iskra Reic

Executive Vice President, Vaccines and Immune Therapies

Aradhana Sarin

Executive Director and Chief Financial Officer

Susan Galbraith

Executive Vice President, Oncology R&D

Mene Pangalos

Executive Vice President, BioPharmaceuticals R&D

Leon Wang

Executive Vice President, International

Appendix

- ESG & corporate sustainability
- Late-stage pipeline: milestones since Q1 2022
- Key performance by geography, disease area





Q2 2022 ESG performance highlights

Access to healthcare

6.3m

lives saved during the first year of *Vaxzevria* roll-out, more than any other vaccine[1]

27m+

blood pressure screenings through Healthy Heart Africa, since its launch in 2015[2]

One Billion Lives Challenge

As part of the EDISON Alliance Challenge, which focuses on underserved communities, AstraZeneca aims to screen 5 million patients for lung cancer using AI-technology by 2025[3]

Environmental protection

1st

of its kind ground source heat pump – which is installed at the Discovery Center in Cambridge, to be independently certified by the UK government as generating renewable energy[4]

7

countries around the world supported tree planting initiatives as part of the AZ Forest commitment to reforestation

59.3%

Of our current vehicles are green fleet (combined EV and hybrid)

Ethics and transparency

Top 50

companies for Diversity, as recognised by Diversity Inc., a leading assessment of diversity management in corporate America[6]

Gold standard

award from WEConnect International for our commitment to Supplier Diversity & Inclusion, and support for women business owners[7]

Clinical trial diversity study

by Tufts Center for the Study of Drug Development (TCSDD), which explores how to increase racial and ethnic representation, published in Applied Clinical Trials[8].

1. Airfinity (13 July 2022) AstraZeneca and Pfizer/BioNTech saved over 12 million lives in the first year of vaccination [Press Release]. Online: https://www.airfinity.com/insights/astrazeneca-and-pfizer-biontech-saved-over-12-million-lives-in-the-first [Last accessed 14 July 2022] 2. AstraZeneca's Healthy Heart Africa programme is committed to reducing hypertension and the burden of cardiovascular disease, aiming to reach 10 million people with elevated blood pressure across Africa by 2025. 3. AstraZeneca (30 May 2022) Partnership with WEF EDISON Alliance to enhance inclusion and equity across the healthcare ecosystem. Online: https://www.astrazeneca.com/media-centre/articles/2022/partnership-with-wef-edison-alliance-to-enhance-inclusion-and-equity-across-the-healthcare-ecosystem.html# [Last accessed 14 July 2022] 4. AstraZeneca (23 November 2021) AstraZeneca unveils The Discovery Centre (DISC) in Cambridge [Press release]. Online: https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-unveils-the-discovery-centre-disc-in-cambridge.html [Last accessed 14 July 2022] 5. WHO (27 June) Inaugural Meeting of the Alliance on Transformative Action on Climate and Health (ATACH). Online: https://www.who.int/news-room/events/detail/2022/06/27/default-calendar/inaugural-meeting-of-the-alliance-on-transformative-action-on-climate-and-health-(atach) [Last accessed 14 July 2022] 6. DiversityInc (2022) 2022 Tope 50 Companies for Diversity List. Online: https://www.diversityinc.com/diversityinc-top-50-2022/ [Last accessed 14 July 2022] 7. WEConnect International (26 April 2022) WEConnect International Announces Top Global Champion Awardees for Supplier Diversity and Inclusion [Press Release]. Online: https://weconnectinternational.org/weconnect-international-announces-top-global-champion-awardees-for-supplier-diversity-and-inclusion/ [Last accessed 14 July 2022] 8. Florez M. L., Botto E., Foster Z., et al (13 June 2022) Improving Diversity in Clinical Trial Volunteer Participation by Addressing Racial and Ethnic Representation Among the Clinical Research Workforce. Applied Clinical Trial. Online: https://www.appliedclinicaltrialsonline.com/view/improving-diversity-in-clinical-trial-volunteer-participation-by-addressing-racial-and-ethnic-representation-among-the-clinical-research-workforce [Last accessed 14 July 2022]

Pipeline catalysts for 2022 - 2023

Oncology BioPharmaceuticals Rare Disease

	H2 2022	H1 2023	H2 2023
Regulatory decision	***Tagrisso*** – NSCLC (adjuvant) (ADAURA) (JP) ***Imfinzi*** – biliary tract cancer (TOPAZ-1) ***Imfinzi*** – liver cancer (1L) (HIMALAYA) ***Imfinzi*** – NSCLC (1L) (POSEIDON) ***Lynparza*** – gBRCAm breast cancer (adjuvant) (OlympiA) (JP) ***Lynparza*** – prostate cancer (1L) (PROpel) ***Enhertu*** – HER2+ breast cancer (2L) (DESTINY-Breast03) ***Enhertu*** – HER2-low breast cancer (3L) (DESTINY-Breast04) ***Enhertu*** – HER2+ gastric cancer (2L) (DESTINY-Gastric01) (EU) ***Enhertu*** – HER2m NSCLC (2L+) (DESTINY-Lung01) ***Calquence*** – CLL (ELEVATE-TN) (JP) ***Forxiga*** – CKD (DAPA-CKD) (CN) ***Tezspire*** – severe asthma (NAVIGATOR) **PT027** – asthma (MANDALA/DENALI) (US) **nirsevimab** – RSV (MELODY/MEDLEY) (EU) ***Evusheld*** – COVID-19 outpatient treatment (TACKLE) ***Ultomiris*** – gMG (CHAMPION-MG) ***Ultomiris*** – subcutaneous, PNH and aHUS (EU) ***Koselugo*** – NF1-PN (SPRINT) (JP)	***Lynparza*** – ovarian cancer (1L) (PAOLA-1) (CN)	***Soliris*** – gMG (CN) ***Koselugo*** – NF1-PN (SPRINT) (CN)
Regulatory submission and/or acceptance	***Lynparza*** – prostate cancer (1L) (PROpel) (US) ***Enhertu*** – HER2+ breast cancer (3L) (DESTINY-Breast02) ***Enhertu*** – HER2-low breast cancer (3L) (DESTINY-Breast04) (CN) ***Farxiga*** – HFpEF (DELIVER) **eplontersen** – ATTRv-PN (NEURO-TTRansform) (US) **nirsevimab** – RSV (MELODY/MEDLEY) (US) ***Evusheld*** – COVID-19 (TACKLE/PROVENT) (CN) ***Vaxzevria*** – COVID-19 (US) ***Ultomiris*** – NMOSD (CHAMPION-NMOSD)	***Imfinzi*** – NSCLC (unresectable, Stg. III) (PACIFIC-2) ***Imfinzi*** – liver cancer (locoregional) (EMERALD-1) ***Imfinzi*** – liver cancer (adjuvant) (EMERALD-2) ***Imfinzi*** – NSCLC (1L) (PEARL) ***Lynparza*** – gBRCAm breast cancer (adjuvant) (OlympiA) (CN) **capivasertib** – HR+/HER2-neg breast cancer (1L) (CAPItello-291) **Dato-DXd** – NSCLC (3L) (TROPION-Lung01) ***Fasenra*** – EOE (MESSINA) **nirsevimab** – RSV (MELODY/MEDLEY) (JP, CN)	***Tagrisso*** – EGFRm NSCLC (1L) (FLAURA2) ***Tagrisso*** – EGFRm NSCLC (unresectable Stg. III) (LAURA) ***Imfinzi*** – biliary tract cancer (TOPAZ-1) (CN) ***Imfinzi*** – bladder cancer (muscle invasive) (NIAGARA) ***Imfinzi*** – bladder cancer (1L) (NILE) ***Imfinzi*** – liver cancer (locoregional) (EMERALD-1) (CN) ***Imfinzi*** – NSCLC (neoadjuvant) (AEGEAN) ***Imfinzi*** – SCLC (limited-stage) (ADRIATIC) **capivasertib** – TNBC (locally adv./met.) (CAPItello-290) **ALXN1840** – Wilson disease **danicopan** – PNH with extravascular haemolysis
Key Phase III data readouts	***Imfinzi*** – liver cancer (locoregional) (EMERALD-1) ***Imfinzi*** – NSCLC (unresectable, Stg. III) (PACIFIC-2) ***Imfinzi*** – NSCLC (1L) (PEARL) ***Enhertu*** – HER2+ breast cancer (3L) (DESTINY-Breast02) **capivasertib** – HR+/HER2-neg breast cancer (1L) (CAPItello-291) ***Fasenra*** – EOE (MESSINA) ***Soliris*** – Guillain-Barré syndrome	***Tagrisso*** – EGFRm NSCLC (1L) (FLAURA2) ***Tagrisso*** – EGFRm NSCLC (unresectable Stg. III) (LAURA) ***Imfinzi*** – bladder cancer (muscle invasive) (NIAGARA) ***Imfinzi*** – bladder cancer (1L) (NILE) ***Imfinzi*** – NSCLC (neoadjuvant) (AEGEAN) ***Imfinzi*** – liver cancer (adjuvant) (EMERALD-2) ***Imfinzi*** – SCLC (limited-stage) (ADRIATIC) ***Lynparza*** – ovarian cancer (1L) (DUO-O) ***Enhertu*** – HER2-low breast cancer (2L) (DESTINY-Breast06) **Dato-DXd** – NSCLC (3L) (TROPION-Lung01) **roxadustat** – anaemia of myelodysplastic syndrome **danicopan** – PNH with extravascular haemolysis	***Lynparza*** – endometrial cancer (1L) (DUO-E) ***Calquence*** – CLL (ACE-CL-311) ***Calquence*** – MCL (1L) (ECHO) **capivasertib** – TNBC (locally adv./met.) (CAPItello-290) **camizestrant** – HR+/HER2-neg breast cancer (SERENA-6) ***Farxiga*** – myocardial infarction (DAPA-MI) ***Fasenra*** – EGPA (MANDARA) ***Fasenra*** – HES (NATRON)

1L = 1st-line; 2L = 2nd-line; 3L = 3rd-line; NSCLC = non-small cell lung cancer; gBRCAm = germline BRCA mutated; HER2+ = human epidermal growth factor receptor 2 positive; HER2-low = human epidermal growth factor receptor 2 low; CLL = chronic lymphocytic leukaemia; CKD = chronic kidney disease; NF1= neurofibromatosis type 1; PN = plexiform neurofibromas; HFpEF = heart failure with preserved ejection faction; ATTRv-PN = hereditary transthyretin-mediated amyloid polyneuropathy; RSV = respiratory syncytial virus; NMOSD = neuromyelitis optica spectrum disorder; HR+ = hormone receptor-positive; HER2-neg = human epidermal growth factor receptor 2 negative; Dato-DXd = datopotamab deruxtecan; EOE = eosinophilic oesophagitis; EGFRm = epidermal growth factor receptor mutated; SCLC = small cell lung cancer; PNH = paroxysmal nocturnal haemoglobinuria; TNBC = triple negative breast cancer; MCL = mantle cell lymphoma; EGPA = eosinophilic granulomatosis with polyangiitis; HES = hyper eosinophilic syndrome.

Q2 2022 Total Revenue performance

Strength and resilience from diverse portfolio and broad revenue base across geographies

Growth across disease areas

Total Revenue ($m)



Growth across geographies

Total Revenue ($m)



Total revenue at actual exchange rates; changes at CER. R&I = Respiratory & Immunology; CVRM = Cardiovascular, Renal & Metabolism; V&I = Vaccines & Immune Therapies; US = United States; ERoW = Established Rest of World; *Koselugo* is now reported in Rare Disease, and *Andexxa* is now reported in the CVRM disease area. In previous results announcements, *Koselugo* was included in the Oncology disease area and *Andexxa* was included in Rare Disease.

Oncology

Tagrisso

14% growth to $2,704m



	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023
EM	315	355	258	306	390	315	325	406	400
ERoW	202	203	232	203	234	232	245	207	231
Europe	163	178	245	225	244	259	258	252	256
US	354	419	422	415	438	441	486	439	513

Imfinzi

16% growth to $1,294m



	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023
EM	30	50	45	58	75	78	65	58	75
ERoW	82	85	95	97	106	101	101	101	104
Europe	93	87	115	109	118	120	138	125	142
US	287	311	300	292	305	319	330	315	374

Oncology

Lynparza

18% growth to $1,291m (excludes Collaboration Revenue)



	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
				2021				2022	
EM	64	75	69	87	99	96	103	121	120
ERoW	50	51	58	54	67	67	71	66	72
Europe	96	114	124	149	153	155	161	160	169
US	209	224	245	253	269	270	294	270	312

Lynparza

Collaboration Revenue: $3.6bn recorded, $4.0bn future potential



	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
	2017		2018				2019				2020				2021				2022	
Sales Milestone	0	0	0	100	0	150	0	0	200	250	0	0	0	300	0	0	0	400	0	0
Regulatory Milestone	0	0	70	0	0	70	0	61	0	0	0	135	0	25	0	0	0	0	175	0
Option Payments	0	250	0	0	0	400	0	0	0	100	0	0	0	0	0	0	0	0	0	0
Upfront	949	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Oncology

Calquence

87% growth to $903m



	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
EM	1	2	2	2	5	5	8	7	8
ERoW	-1	1	2	3	3	4	8	13	18
Europe	0	0	2	9	22	37	43	55	67
US	107	142	176	195	250	308	336	339	396

Enhertu

>2x growth to $204m



	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
EM	0	0	0	1	3	4	5	9	17
ERoW	0	0	0	0	0	0	0	1	2
Europe	0	0	2	4	6	9	13	20	26
US	22	26	31	35	40	45	49	57	73

BioPharmaceuticals: Cardiovascular, Renal and Metabolism

Farxiga

63% growth to $2,103m



	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023
EM	165	181	198	260	297	320	318	391	423
ERoW	49	56	61	60	68	63	78	99	98
Europe	107	141	144	174	198	213	225	318	309
US	124	148	184	131	171	202	228	193	275

Brilinta

7% decline to $675m



	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023
EM	156	102	69	105	74	76	71	69	78
ERoW	14	14	14	15	17	16	16	14	14
Europe	80	84	85	88	90	85	83	76	73
US	187	185	195	166	194	198	178	166	185

Lokelma

87% growth to $129m



	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023
EM	1	2	1	1	1	1	0	3	2
ERoW	3	2	5	6	10	13	15	15	18
Europe	1	1	2	2	3	3	5	6	7
US	12	16	20	24	25	32	34	39	39

BioPharmaceuticals: Respiratory & Immunology

Symbicort

3% decline to $1,288m



	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
EM	135	132	145	165	141	151	152	167	139
ERoW	109	105	95	92	99	96	96	91	98
Europe	161	165	173	168	176	155	171	157	155
US	248	197	267	266	264	274	262	259	222

Fasenra

18% growth to $662m



	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2
EM	1	3	2	3	5	7	5	7	10
ERoW	32	34	38	38	41	41	43	37	36
Europe	42	52	63	63	73	75	75	75	78
US	152	151	180	156	201	199	234	189	230

BioPharmaceuticals: Respiratory & Immunology

Breztri

>2x growth to $179m



	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023
EM	5	5	-1	9	17	14	15	22	21
ERoW	2	2	5	5	7	6	8	7	10
Europe	0	0	0	1	1	2	3	5	9
US	0	3	2	12	31	25	47	53	53

Pulmicort

32% decline to $334m



	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023
EM	58	109	319	286	119	173	193	164	72
ERoW	11	11	13	11	12	12	13	13	12
Europe	15	14	18	16	18	15	23	18	17
US	13	17	18	17	18	17	19	22	15

Rare Disease

Soliris

1% growth at $2,017m



	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023
EM	0	0	0	0	0	53	117	71	63
ERoW	0	0	0	0	0	86	111	107	174
Europe	0	0	0	0	0	199	240	221	216
US	0	0	0	0	0	460	608	591	574

Ultomiris

28% growth to $853m



	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023
EM	0	0	0	0	0	5	4	24	6
ERoW	0	0	0	0	0	56	73	70	72
Europe	0	0	0	0	0	69	100	105	120
US	0	0	0	0	0	167	214	220	236

Strensiq

13% growth to $450m



	Q2 2021	Q3 2021	Q4 2021	Q1 2022	Q2 2022	Q3 2022	Q4 2022	Q1 2023	Q2 2023
EM	0	0	0	0	0	4	6	9	9
ERoW	0	0	0	0	0	15	20	19	19
Europe	0	0	0	0	0	16	20	19	21
US	0	0	0	0	0	124	173	161	193

Q3 2021 Total Revenues reported only comprise of those booked by AstraZeneca following completion of the acquisition of Alexion on 21 July 2021.

Use of AstraZeneca slides from conference calls and webcasts

The AstraZeneca webcast, conference call and presentation slides (together the 'AstraZeneca materials') are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast, transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca materials in any way. You may not edit, alter, adapt or add to the AstraZeneca materials in any way, nor combine the AstraZeneca materials with any other material. You may not download or use the AstraZeneca materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any third party) and us, our agents or employees, or any contributors to the AstraZeneca materials. You may not use the AstraZeneca materials in any way that could bring our name or that of any Affiliate into disrepute or otherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone + 44 20 3749 5000, www.astrazeneca.com